Sure, email away :) I'll copy this here, my ans
Post# of 155256
(Total Views: 438)
Posted On: 05/28/2019 7:11:11 AM
Sure, email away 
I'll copy this here, my answer on ihub to "so what?", for completion.
For cancer it is very likely only happen after the first results, though results on the other 8 preclinical studies might help. This issue is only 3%-8% of preclinical studies translate to clinical, so they are getting very little credit
But my points
1) This could be very very big. Much bigger than TNBC. All cancers are in play, with the very high ccr5 expression connected to metastasis for that cancer. That percent could be as low as 20% for a particular cancer type with high ccr5 expression, but 20% of all cancers is a massive number. And if this works, I'd imagine with moderate ccr5 expression is in play.
They choose TNBC because 1) the unmet need making it faster to approval and 2) the high percentage with TNBC that are ccr5 (which I feel is the reason TNBC is so deadly to start with)
2) There are many reasons the preclinical don't translate to clinical. Most are safety issues (which I'm not concerned with), the wrong mice, experiment done incorrectly, wrong dose, etc, etc. With this being shown is almost all common cancers over many different mice models, with many different independent researchers, with many different ccr5 inhibitors, a lot of that risk has been eliminated. RP said the results with leronlimab in the TNBC is amazing, something he has either rarely or never seen in 35 years. So right now I have been not looking at the percentage of success, but the percentage of failure if something has this big of results in this many cancers across this many models. I'm reading to see, I have found a couple links that connects the number of types of preclinical cancer success with drugs that are still in clinical trials (not failed yet). Each cancer type has a correlation, small-lung being the best predictor. But what if it was successful in all preclincial trials? I think our success rate is much higher and has not been factored into the stock price yet.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC...91796a.pdf
I'll copy this here, my answer on ihub to "so what?", for completion.
Quote:
At what point are going all in on this stock? Before FDA approval? After first TNBC results? After "funding secured"?
For cancer it is very likely only happen after the first results, though results on the other 8 preclinical studies might help. This issue is only 3%-8% of preclinical studies translate to clinical, so they are getting very little credit
But my points
1) This could be very very big. Much bigger than TNBC. All cancers are in play, with the very high ccr5 expression connected to metastasis for that cancer. That percent could be as low as 20% for a particular cancer type with high ccr5 expression, but 20% of all cancers is a massive number. And if this works, I'd imagine with moderate ccr5 expression is in play.
They choose TNBC because 1) the unmet need making it faster to approval and 2) the high percentage with TNBC that are ccr5 (which I feel is the reason TNBC is so deadly to start with)
2) There are many reasons the preclinical don't translate to clinical. Most are safety issues (which I'm not concerned with), the wrong mice, experiment done incorrectly, wrong dose, etc, etc. With this being shown is almost all common cancers over many different mice models, with many different independent researchers, with many different ccr5 inhibitors, a lot of that risk has been eliminated. RP said the results with leronlimab in the TNBC is amazing, something he has either rarely or never seen in 35 years. So right now I have been not looking at the percentage of success, but the percentage of failure if something has this big of results in this many cancers across this many models. I'm reading to see, I have found a couple links that connects the number of types of preclinical cancer success with drugs that are still in clinical trials (not failed yet). Each cancer type has a correlation, small-lung being the best predictor. But what if it was successful in all preclincial trials? I think our success rate is much higher and has not been factored into the stock price yet.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC...91796a.pdf
(0)
(0)